OBJECTIVE： To investigate clinical efficacy and safety of Xuebijing injection in the treatment of chronic obstructive pulmonary disease （COPD） complicated with community-acquired pneumonia （CAP）. METHODS： A total of 88 COPD patients with CAP selected from our hospital during Feb. 2013-Jan. 2015 were divided into control group and observation group according to random number table， with 44 cases in each group. Control group received routine treatment as anti-infection， reducing phlegm， fluid replacement， nutritional support， etc. Based on control group， observation group was additionally given Xuebijing injection 50 mL added into 0.9％ Sodium chloride injection 100 mL， ivgtt， for 30-40 min， bid， for consecutive 10 d. Clinical efficacy， application time of antibiotics， pulmonary function indexes [FEV1， FVC， FEV1/FVC， VC] were observed in 2 groups. The occurrence of ADR was recorded. RESULTS： Total response rate of observation group was 88.64％， which was significantly higher than 70.45％ of control group， with statistical significance （P＜0.05）. The application time of antibiotics in observation group was significantly shorter than control group， with statistical significance （P＜0.05）. There was no statistical significance in FEV1， FVC， FEV1/FVC， VC between 2 groups before treatment （P＞0.05）. After treatment， FEV1 and VC of 2 groups were improved significantly， and the observation group was better than the control group， with statistical significance （P＜0.05）. There was no statistical significance in FVC， FEV1/EVC before and after treatment and betwean the two groups （P＞0.05）.  No obvious ADR was found in 2 groups. CONCLUSIONS： Xuebijing injection has significant therapeutic efficacy for COPD complicated with CAP and can significantly shorten the use time of antibiotics， improve pulmonary function with good safety.